NCI-Sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: Safety studies

Alexander M. Spence, Mark Muzi, Jeanne Link, John M. Hoffman, Janet F. Eary, Kenneth Krohn

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose: 3′-[F-18]Fluoro-3′-deoxythymidine (FLT) is an analog of thymidine that is being developed for imaging cellular proliferation. The goal of this study was to prove that the dose of FLT used for positron emission tomography imaging produces no significant toxicity. Procedures: Twelve patients with gliomas with either recurrence or suspected radionecrosis were imaged with FLT. Before and at several time points after imaging, subjects underwent general physical and neurological examinations with review of systems and tests of hematologic, hepatic, renal, and several other metabolic parameters. Vital signs and electrocardiograms were monitored during and after the imaging session. Results: There were no significant adverse effects from FLT injected at a dose of 0.07 mCi/kg (maximum of 5 mCi) at specific activities of 1.25 Ci/μmol or higher. The FLT mass administered for imaging was 0.0001% to 0.0009% of the least toxic cumulative dose administered in clinical trials of FLT as an antiretroviral agent. Conclusions: FLT is a safe radiotracer for quantifying proliferation in the human cancer setting.

Original languageEnglish (US)
Pages (from-to)271-280
Number of pages10
JournalMolecular Imaging and Biology
Volume10
Issue number5
DOIs
StatePublished - 2008
Externally publishedYes

Fingerprint

Anti-Retroviral Agents
Vital Signs
Poisons
Neurologic Examination
Hematologic Tests
Glioma
Positron-Emission Tomography
Thymidine
Physical Examination
Electrocardiography
Cell Proliferation
Clinical Trials
Kidney
Safety
Recurrence
Liver
Neoplasms
alovudine

Keywords

  • 3′-[F-18]fluoro-3′-deoxythymidine
  • FLT
  • Fluorothymidine
  • Glioblastoma
  • Glioma
  • Positron emission tomography (PET)
  • Proliferation
  • Safety
  • Toxicity

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Radiology Nuclear Medicine and imaging

Cite this

NCI-Sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas : Safety studies. / Spence, Alexander M.; Muzi, Mark; Link, Jeanne; Hoffman, John M.; Eary, Janet F.; Krohn, Kenneth.

In: Molecular Imaging and Biology, Vol. 10, No. 5, 2008, p. 271-280.

Research output: Contribution to journalArticle

@article{39d13ef056ae48ec932174a410b81236,
title = "NCI-Sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: Safety studies",
abstract = "Purpose: 3′-[F-18]Fluoro-3′-deoxythymidine (FLT) is an analog of thymidine that is being developed for imaging cellular proliferation. The goal of this study was to prove that the dose of FLT used for positron emission tomography imaging produces no significant toxicity. Procedures: Twelve patients with gliomas with either recurrence or suspected radionecrosis were imaged with FLT. Before and at several time points after imaging, subjects underwent general physical and neurological examinations with review of systems and tests of hematologic, hepatic, renal, and several other metabolic parameters. Vital signs and electrocardiograms were monitored during and after the imaging session. Results: There were no significant adverse effects from FLT injected at a dose of 0.07 mCi/kg (maximum of 5 mCi) at specific activities of 1.25 Ci/μmol or higher. The FLT mass administered for imaging was 0.0001{\%} to 0.0009{\%} of the least toxic cumulative dose administered in clinical trials of FLT as an antiretroviral agent. Conclusions: FLT is a safe radiotracer for quantifying proliferation in the human cancer setting.",
keywords = "3′-[F-18]fluoro-3′-deoxythymidine, FLT, Fluorothymidine, Glioblastoma, Glioma, Positron emission tomography (PET), Proliferation, Safety, Toxicity",
author = "Spence, {Alexander M.} and Mark Muzi and Jeanne Link and Hoffman, {John M.} and Eary, {Janet F.} and Kenneth Krohn",
year = "2008",
doi = "10.1007/s11307-008-0151-6",
language = "English (US)",
volume = "10",
pages = "271--280",
journal = "Molecular Imaging and Biology",
issn = "1536-1632",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - NCI-Sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas

T2 - Safety studies

AU - Spence, Alexander M.

AU - Muzi, Mark

AU - Link, Jeanne

AU - Hoffman, John M.

AU - Eary, Janet F.

AU - Krohn, Kenneth

PY - 2008

Y1 - 2008

N2 - Purpose: 3′-[F-18]Fluoro-3′-deoxythymidine (FLT) is an analog of thymidine that is being developed for imaging cellular proliferation. The goal of this study was to prove that the dose of FLT used for positron emission tomography imaging produces no significant toxicity. Procedures: Twelve patients with gliomas with either recurrence or suspected radionecrosis were imaged with FLT. Before and at several time points after imaging, subjects underwent general physical and neurological examinations with review of systems and tests of hematologic, hepatic, renal, and several other metabolic parameters. Vital signs and electrocardiograms were monitored during and after the imaging session. Results: There were no significant adverse effects from FLT injected at a dose of 0.07 mCi/kg (maximum of 5 mCi) at specific activities of 1.25 Ci/μmol or higher. The FLT mass administered for imaging was 0.0001% to 0.0009% of the least toxic cumulative dose administered in clinical trials of FLT as an antiretroviral agent. Conclusions: FLT is a safe radiotracer for quantifying proliferation in the human cancer setting.

AB - Purpose: 3′-[F-18]Fluoro-3′-deoxythymidine (FLT) is an analog of thymidine that is being developed for imaging cellular proliferation. The goal of this study was to prove that the dose of FLT used for positron emission tomography imaging produces no significant toxicity. Procedures: Twelve patients with gliomas with either recurrence or suspected radionecrosis were imaged with FLT. Before and at several time points after imaging, subjects underwent general physical and neurological examinations with review of systems and tests of hematologic, hepatic, renal, and several other metabolic parameters. Vital signs and electrocardiograms were monitored during and after the imaging session. Results: There were no significant adverse effects from FLT injected at a dose of 0.07 mCi/kg (maximum of 5 mCi) at specific activities of 1.25 Ci/μmol or higher. The FLT mass administered for imaging was 0.0001% to 0.0009% of the least toxic cumulative dose administered in clinical trials of FLT as an antiretroviral agent. Conclusions: FLT is a safe radiotracer for quantifying proliferation in the human cancer setting.

KW - 3′-[F-18]fluoro-3′-deoxythymidine

KW - FLT

KW - Fluorothymidine

KW - Glioblastoma

KW - Glioma

KW - Positron emission tomography (PET)

KW - Proliferation

KW - Safety

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=49149108259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49149108259&partnerID=8YFLogxK

U2 - 10.1007/s11307-008-0151-6

DO - 10.1007/s11307-008-0151-6

M3 - Article

C2 - 18543042

AN - SCOPUS:49149108259

VL - 10

SP - 271

EP - 280

JO - Molecular Imaging and Biology

JF - Molecular Imaging and Biology

SN - 1536-1632

IS - 5

ER -